Literature DB >> 6436012

Chronic exposure of cultured rat anterior pituitary cells to GRF causes partial loss of responsiveness to GRF.

L M Bilezikjian, W W Vale.   

Abstract

Pretreatment of primary cultures of rat anterior pituitary cells with 500 pM rhGRF for 24 h resulted in a partial loss of responsiveness to GRF. When pretreated cells were rechallenged with increasing concentrations of rhGRF, maximal GH secretion was significantly lower than control, since prolonged exposure to the peptide resulted in depletion of releasable GH pools: 3.04 +/- 0.39 and 0.63 +/- 0.08 micrograms GH per 0.15 X 10(6) cells in control and treated cells, respectively. Possible desensitization, however, was indicated, since chronic exposure to rhGRF increased the EC50 for GH secretion by 5.5-fold. Pretreatment with 2 mM 8BrcAMP for 24 h also caused significant depletion of cellular GH. Consequently, maximal GH secretory response of these cells was blunted as well. However, in contrast to rhGRF-pretreatment, 8BrcAMP-pretreatment did not significantly affect the EC50 value for GH secretion. As another index for cellular responsiveness, cAMP production was also monitored. After a 24-h incubation with 500 pM rhGRF, attenuation of adenylate cyclase activity was evident, since the EC50 value for cAMP production was 2.8-fold greater than control. These results suggest that prolonged pretreatment with GRF results in a partial loss of responsiveness to GRF and this may be explained by desensitization and to some extent by depletion of GH stores.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6436012     DOI: 10.1210/endo-115-5-2032

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  12 in total

1.  Growth hormone and prolactin responses to bolus and sustained infusions of GRH-1-40-OH in man.

Authors:  J A Goldman; M E Molitch; M O Thorner; W Vale; J Rivier; S Reichlin
Journal:  J Endocrinol Invest       Date:  1987-08       Impact factor: 4.256

2.  GH responsiveness to repeated GHRH or hexarelin administration in normal adults.

Authors:  A Sartorio; A Conti; S Ferrero; A Spada; G Faglia
Journal:  J Endocrinol Invest       Date:  1995-10       Impact factor: 4.256

Review 3.  Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.

Authors:  Monica Gola; Mauro Doga; Stefania Bonadonna; Gherardo Mazziotti; Pier Paolo Vescovi; Andrea Giustina
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

4.  Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro.

Authors:  N Billestrup; L W Swanson; W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

5.  Dominant dwarfism in transgenic rats by targeting human growth hormone (GH) expression to hypothalamic GH-releasing factor neurons.

Authors:  D M Flavell; T Wells; S E Wells; D F Carmignac; G B Thomas; I C Robinson
Journal:  EMBO J       Date:  1996-08-01       Impact factor: 11.598

6.  Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.

Authors:  M L Vance; D L Kaiser; W S Evans; R Furlanetto; W Vale; J Rivier; M O Thorner
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

7.  Galanin infusion partially restores the blunted growth hormone responses to repeated growth hormone releasing hormone stimuli in normal adults.

Authors:  A Sartorio; A Spada; A Conti; G Grugni; F Morabito; G Faglia
Journal:  J Endocrinol Invest       Date:  1993-02       Impact factor: 4.256

Review 8.  Somatostatin and somatostatin receptor physiology.

Authors:  Philip Barnett
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

9.  Growth hormone-releasing hormone stimulates cAMP release in superfused rat pituitary cells.

Authors:  J E Horváth; K Groot; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

10.  Different GH responsiveness to repeated GHRH administration in normal children and adults.

Authors:  A Sartorio; A Spada; F Morabito; G Faglia
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.